Brief: HBM Holdings Says Unit Entered License & Option Agreement With Astrazeneca
23/05/2024 02:09
May 23 (Reuters) - Hbm Holdings Ltd 2142.HK :
* UNIT ENTERED LICENSE & OPTION AGREEMENT WITH ASTRAZENECA
FOR
NOVEL TUMOR TARGETED THERAPIES
* UNIT NONA BIOSCIENCES TO GET UPFRONT PAYMENTS OF US$19
MILLION
ON COMPLETION OF DEAL
Further company coverage: 2142.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on HBM Holdings
See all newsBrief: HBM Holdings Says NMPA Approves Batoclimab Injection For Generalized Myasthenia Gravis
HBM climbs on development of AI biology foundation model
Brief: HBM Holdings' Unit Develops World's First Language Model For Fully Human Heavy-Chain-Only Antibodies
Brief: Hbm Holdings Says Solstice Oncology Launches Series A Financing Round
HK-listed HBM climbs on initiating next phase of asthma drug study